Legal & General Group Plc Purchases 172,129 Shares of Indivior PLC $INDV

Legal & General Group Plc lifted its stake in shares of Indivior PLC (NASDAQ:INDV) by 127.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 307,650 shares of the company’s stock after purchasing an additional 172,129 shares during the quarter. Legal & General Group Plc owned about 0.25% of Indivior worth $10,755,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Oaktree Capital Management LP boosted its position in shares of Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after purchasing an additional 246,776,273 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. Rubric Capital Management LP boosted its position in shares of Indivior by 31.6% during the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after purchasing an additional 1,117,140 shares in the last quarter. Finally, Newtyn Management LLC boosted its position in shares of Indivior by 61.1% during the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after purchasing an additional 1,592,982 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

INDV opened at $35.43 on Thursday. Indivior PLC has a fifty-two week low of $12.81 and a fifty-two week high of $41.00. The firm has a market capitalization of $4.32 billion, a PE ratio of 18.17 and a beta of 0.88. The company’s 50-day moving average is $34.29 and its 200 day moving average is $34.02.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The company had revenue of $317.00 million for the quarter. As a group, analysts expect that Indivior PLC will post 4.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on INDV shares. Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $39.33.

Insider Buying and Selling

In other news, Director Stuart A. Kingsley acquired 940 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was purchased at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the purchase, the director owned 5,582 shares in the company, valued at approximately $177,842.52. This represents a 20.25% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.74% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.